Roscovitine, a Cdk5 inhibitor purchased from Santa Cruz Biotechnology, Inc., was dissolved in 20% dimethylsulfoxide (physiological salt solution). The induction of anesthesia was performed in a small induction chamber, where the flow of oxygen-4% isoflurane is 2 l/min for 3-4.5 min. After 3 min, the foot was gently pinched with tweezers at 30-sec intervals to test the anesthesia state. Roscovitine (50 or 100 µg in 10 µl of 20% physiological salt solution) or the same volume of physiological salt solution was intracerebroventricularly administered into each rat at 30 min after sham injury or SAH during, which a new 1.0-mm lateral hole at 1.5 mm behind the bregma was made, through which the drug was administered. The drug dose utilized in this study was selected based on a previous study using a traumatic brain injury model (26 (link)).